AbbVie Inc. (NYSE:ABBV – Get Free Report) was the target of unusually large options trading activity on Monday. Stock ...

Idexx Laboratories stock was rising sharply Monday, even as the S&P 500 and major indexes remained in the red. The Dow Jones ...

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 per share ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

AbbVie is a Dividend King that has proven its ability to survive and thrive. Intuitive Surgical has a huge market opportunity for its robotic surgical systems. Vertex Pharmaceuticals is leveraging ...

AbbVie was the biopharmaceutical division of Abbott Laboratories until it spun off in 2013. AbbVie has maintained Abbott's decades-long dividend-raising streak and raised the bar for its industry.

Once Humira biosimilars entered the US markets in 2023, drug revenues declined by 32% for AbbVie. Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

AbbVie leaders are “disappointed” with poor results from a schizophrenia drug the company acquired last year that led to a $3.5 billion impairment charge, but they say they aren’t completely ...

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...